4.6 Article

Diabetic ketoacidosis

期刊

NATURE REVIEWS DISEASE PRIMERS
卷 6, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41572-020-0165-1

关键词

-

资金

  1. American Diabetes Association (ADA) [1-17-IBS-186]
  2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U34DK123894]
  3. Fondo Nacional de Ciencia y Tecnologia (FONDECYT) from the Government of Chile [1170895]
  4. National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) from the Clinical and Translational Science Award program [UL1TR002378]
  5. NIH [U30, P30DK11102]
  6. Dexcom
  7. Novo Nordisk
  8. Sanofi

向作者/读者索取更多资源

Diabetic ketoacidosis (DKA) is the most common acute hyperglycaemic emergency in people with diabetes mellitus. A diagnosis of DKA is confirmed when all of the three criteria are present - 'D', either elevated blood glucose levels or a family history of diabetes mellitus; 'K', the presence of high urinary or blood ketoacids; and 'A', a high anion gap metabolic acidosis. Early diagnosis and management are paramount to improve patient outcomes. The mainstays of treatment include restoration of circulating volume, insulin therapy, electrolyte replacement and treatment of any underlying precipitating event. Without optimal treatment, DKA remains a condition with appreciable, although largely preventable, morbidity and mortality. In this Primer, we discuss the epidemiology, pathogenesis, risk factors and diagnosis of DKA and provide practical recommendations for the management of DKA in adults and children.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据